| B29 | Attained stature of HIV exposed Ugandan children by 6-18 years of life according to In-utero or peripartum antiretroviral therapy exposure type | E-poster | Other ART complications and adverse reactions |
| B30 | Opioid agonist treatment improves progression through each stage of the HIV cascade of care among people living with HIV who use opioids | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Depression, anxiety, and polysubstance use among persons with HIV: baseline findings from the Promoting Access to Care Engagement (PACE) trial | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Results from a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia | E-poster | Substance abuse (including opioid use disorder) |
| B30 | Anxiety and alcohol consumption in the Miami Adult Studies on HIV (MASH) cohort during the COVID-19 pandemic | E-poster | Substance abuse (including opioid use disorder) |
| B31 | OPTIPRIM 2-ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infection | E-poster | ART in acute infection |
| B32 | Integrase strand transfer inhibitor (INSTI) use and cancer incidence | E-poster | ART in first- and second-line therapies |
| B32 | Antiretroviral therapy for HIV controllers: indications and outcomes in the French ANRS-CO21 CODEX cohort | E-poster | ART in first- and second-line therapies |
| B32 | Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine? | E-poster | ART in first- and second-line therapies |
| B32 | High rates of viral suppression sixteen weeks after transition from EFV- to DTG-based ART regardless of viral load at transition: the DO-REAL cohort study in Lesotho | E-poster | ART in first- and second-line therapies |